C4 Therapeutics amends bylaws to designate exclusive forum for federal securities claims

C4 Therapeutics, Inc.

Board approved by-laws amendment effective April 9, 2026 designating U.S. District Courts for Massachusetts and Delaware as exclusive forums for Securities Act and Exchange Act claims.
Amendment responds to recent changes in Delaware General Corporation Law regarding forum selection provisions.
Company may consent in writing to an alternative forum; full text filed as Exhibit 3.1.
No financial impact; governance change only.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

C4 Therapeutics, Inc.: Amended bylaws to designate exclusive federal forum for Securities Act and Exchange Act claims, effective immediately (effective 2026-04-09).

Change: bylaw amendment
Effective: 2026-04-09

Exact text from the filing

On April 9, 2026, the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s second amended and restated by-laws (the “By-laws Amendment”), effective immediately, to designate the United States District Court for the District of Massachusetts and the United States District Court for the District of Delaware as the exclusive forums for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-024583

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.